 |
|
Relationship Between Disease-Free Interval and Survival in Patients With Recurrent Melanoma
Nancy J. Crowley, MD;
Hilliard F. Seigler, MD
Arch Surg. 1992;127(11):1303-1308.
Abstract
• A total of 2468 patients with recurrent melanoma were subdivided on the basis of disease-free interval: group 1 had recurrences within 1 year (n=810), group 2 at years 1 to 3 (n=1001), group 3 at years 3 to 5 (n=363), group 4 at years 5 to 10 (n=329), and group 5 after 10 years (n=145). Ten-year survivals were 21%, 23%, 25%, 28%, and 35%, respectively. Patients who had recurrences within 1 year had a decreased median survival compared with those who had later recurrences, although the differences were not clinically significant (only 6 to 8 months). Survival was improved for the few patients who had recurrences longer than 10 years from diagnosis. However, for the majority of patients, who had recurrences between 1 and 10 years, the disease-free interval did not predict subsequent survival. The data support the hypothesis that malignant cells can exist in a state of relative quiescence for extended periods. Once disease reactivation occurs, however, the subsequent survival is relatively predictable and is independent of the initial period of tumor dormancy.
(Arch Surg. 1992;127:1303-1308)
Author Affiliations
From the Department of Surgery, Duke University Medical Center, Durham, NC.
Footnotes
Accepted for publication July 9, 1992.
Presented at the 45th Annual Cancer Symposium of the Society of Surgical Oncology, New York, NY, March 17, 1992.
Reprint requests to Box 3279, Duke University Medical Center, Durham, NC 27710 (Dr Crowley).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Metastatic adenocarcinoma after intramedullary fixation of a tibial fracture: A REPORT OF TWO CASES
Ahmed et al.
J Bone Joint Surg Br 2010;92-B:1592-1595.
ABSTRACT
| FULL TEXT
Cancer Stem Cells and Aneuploid Populations within Developing Tumors Are the Major Determinants of Tumor Dormancy
Kusumbe and Bapat
Cancer Res. 2009;69:9245-9253.
ABSTRACT
| FULL TEXT
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype.
Naumov et al.
JNCI J Natl Cancer Inst 2006;98:316-325.
ABSTRACT
| FULL TEXT
Therapy of Hematogenous Melanoma Brain Metastases with Endostatin
Kirsch et al.
Clin. Cancer Res. 2005;11:1259-1267.
ABSTRACT
| FULL TEXT
Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy
UDAGAWA et al.
FASEB J. 2002;16:1361-1370.
ABSTRACT
| FULL TEXT
Persistence of Solitary Mammary Carcinoma Cells in a Secondary Site: A Possible Contributor to Dormancy
Naumov et al.
Cancer Res. 2002;62:2162-2168.
ABSTRACT
| FULL TEXT
Tumor Vascularity, Proliferation, and Apoptosis in Human Melanoma Micrometastases and Macrometastases
Barnhill et al.
Arch Dermatol 1998;134:991-994.
ABSTRACT
| FULL TEXT
Malignant Melanoma in Children: A Review
Ruiz-Maldonado and de la Luz Orozco-Covarrubias
Arch Dermatol 1997;133:363-371.
ABSTRACT
|
